Abstract
Disposition of [125I]rHu-TNF was elucidated in BALB/c mice bearing Meth A fibrosarcoma 7 days after transplantation. Afteri.v. administration, [125I]rHu-TNF measured by radioactivity and immunoreactivity biphasically decreased in plasma. Tumor level of [125I]rHu-TNF was the maximum at 1 h, then decreased and finally remained essentially constant. After i.t. administration, plasma level reached the maximum at 1 h. Tumor level decreased quickly and then became essentially constant. [125I]rHu-TNF was suggested to be degraded to small fragments in the tumor. Significant distribution of [125I]rHu-TNF was found in the kidney, lung, liver and tumor. Most tissue levels decreased with time in parallel with plasma levels. [125I]rHu-TNF radioactivity was found in proximal convoluted tubules of kidney and in those areas of tumor consisting of degenerating cells with pyknotic nuclei. Urine contained most of administered radioactivity, which being neither immunoreactive nor protein-bound.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Abbreviations
- AUC:
-
area under plasma level-time curve
- EIA:
-
enzyme-immunoassay
- H-E:
-
hematoxylin-eosin
- HSA:
-
human serum albumin
- i.t. :
-
intratumoral
- i.v. :
-
intravenous
- PAS:
-
periodic acid-Schiff
- TNF:
-
tumor necrosis factor
- rHu-TNF:
-
recombinant human TNF
References
Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced serum factor that causes necrosis of tumor. Proc Natl Acad Sci USA 1975; 72: 3666–70.
Old LJ. Tumor necrosis factor (TNF). Science (Wash DC) 1985; 230: 630–32.
Taguchi T. A phase I study of recombinant human tumor necrosis factor (rHu-TNF: PT-050) (in Japanese). Jpn J Cancer Chemother 1986; 13: 3491–97.
Yamada M, Furutani Y, Notake M, Yamagishi J, Yamayoahi M, Fukui T, Nomura H, Komiya M, Kuwashima J, Nakano K, Sohmura Y, Nakamura S. Efficient production of human tumor necrosis factor inEscherichia coli. J Biothechnol 1985; 3: 141–53.
Yamazaki S, Onishi E, Enami K, Natori K, Kohase M, Sakamoto H, Tanouchi M, Hayashi H. Proposal of standardized method and reference for assaying recombinant human tumor necrosis factor. Jpn J Med Sci Biol 1986; 39: 105–18.
Michelot R, Gozlan H, Beaujouan JC, Besson MJ, Torrens Y, Glowinski J. Synthesis and biological activities of substance P iodinated derivatives. Biochem Biophys Res Comm 1980; 95: 491–98.
Hunter WM, Greenwood FC. Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature (London) 1962; 194: 495–96.
Bolton AE, Hunter WM. The labelling of proteins to high specific radioactivities by conjugation to a125I-containing acylating agent. Biochem J 1973; 133: 529–39.
Wingfield P, Pain RH, Craig S. Tumor necrosis factor is a compact trimer. FEBS Letter 1987; 211: 179–84.
Sohmura Y, Nakata K, Yoshida H, Kashimoto S, Matsui Y, Furuichi H. Recombinant human tumor necrosis factor-II. Antitumor effect on murine and human tumors transplanted in mice. Int J Immunopharmac 1986; 8: 357–68.
Kurooka S, Sunahara N. Insolubilized antibody. US Patent 1979; 4,166,769.
Kitagawa T, Aikawa T. Enzyme coupled immunoassay of insulin using a novel coupling agent. J Biochem (Tokyo) 1976; 79: 233–36.
Hayashi S, Kurooka S, Arisue K, Kohda K, Hayashi C. Semi-automated continuous-flow enzyme immunoassay for antiepileptic drugs in serum. Clin Chem 1983; 29: 1790–92.
Yamaoka K, Tanigawara Y. Microcomputer programs for pharmacokinetics (in Japanese). Tokyo: Nankodo Pub Co Ltd, 1983.
Nakano K, Abe S, Sohmura Y. Recombinant human tumor necrosis factor I. Cytotoxic activityin vitro. Int J Immunopharmac 1986; 8: 347–55.
Miyazaki H, Iida M, Matsunaga Y, Fujii T, Nambu K, Amejima H, Oh-e Y, Furukawa H, Matsui Y, Sohmura Y, Hashimoto M. Mode of antitumor action of recombinant human tumor necrosis factor on the sarcoma Meth A transplanted in the mouse. Biotherapy (submitted).
Tsujimoto M, Yip YK, Vilcek J. Tumor necrosis factor: Specific binding and internalization in sensitive and resistant cells. Proc Natl Acad Sci USA 1985; 82: 7626–30.
Stacy BD, Wallace ALC, Gemmel RT, Wilson BW. Absorption of125I-labelled sheep growth hormone in single proximal tubules of the rat kidney. J Endocrinol 1976; 68: 21–30.
Maunsbach AB. Absorption of125I-labeled homologous albumin by rat kidney proximal tubule cells. J Ultrastr Res 1966; 15: 197–241.
Pessina GP, Pacini A, Bocci V, Maioli E, Naldini A. Studies on tumor necrosis factor (TNF): II. Metabolic fate and distribution of human recombinant TNF. Lymphokine Res 1987; 6: 35–44.
Miyazaki H, Matsunaga Y, Hashimoto M. Distribution of [14]labeled purines in the mouse: A whole body autoradiographic assessment of purine metabolism in mammals. J Histochem Cytochem 1978; 26: 663–76.
Bogoloch R. Liquid emulsion autoradiography. In: Gahan PB, ed. Autoradiography for biologists. London, New York: Academic Press Inc., 1982: 65–94.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Miyazaki, H., Fujii, T., Amejima, H. et al. Disposition of125I-labeled recombinant human tumor necrosis factor in the tumor-bearing mouse. Biotherapy 1, 7–18 (1989). https://doi.org/10.1007/BF02170131
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02170131